Hearing recovery occurred in 90 percent of gene therapy patients with OTOF-related hearing loss, with particular improvements in children.

The firm is planning to begin a Phase III study evaluating zovegalisib, atirmociclib, and an aromatase inhibitor in early 2027.

"Epitopea's CryptiVax-1001 vaccine, which targets a novel repertoire of tumor-specific antigens, has the potential to meaningfully extend remission for patients with few effective treatment options," ...

The firm is expecting to hear from the agency in August after submitting data showing Ziihera combinations bested trastuzumab and chemo.

The firm expects its treatment for hereditary angioedema, known as lonvo-z, will be the first in vivo CRISPR gene-editing therapy to reach the market.

The firm closed an oversubscribed Series B financing round to fund a pivotal trial of RTx-015 and advance a clinical trial in ...

The European Commission will now consider the committee's positive opinions as it determines whether to grant marketing authorization to the drugs.

NEW YORK – Create Medicines has started clinically testing an in vivo CAR therapy that comprises a cancer-killing medley of T, NK, and myeloid cells.

The firm said the CHMP would not support the application due to concerns about the control arm used in the Phase III PSMAfore trial.

Regeneron's Otarmeni is the first gene therapy approved for OTOF-related hearing loss, which the firm said it will provide to ...

Four of nine patients responded to the mesothelin-directed therapy, which uses a multi-chain receptor borrowed from NK cells, ...

Company execs still have high hopes for the SERD giredestrant, despite a recent trial failure in first-line metastatic breast ...